Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030

UF Startup Kate Therapeutics, a gene therapy specialist, is being acquired by Novartis in a deal worth up to $1.1 billion. This acquisition aligns with Novartis’s efforts to deliver treatments for neuromuscular disorders and fits into the pharma’s strategy to expand its new modality pipeline, ensuring long-term business sustainability.

GatorPitch Showcases University of Florida Startups in Miami

UF Innovate hosted its inaugural GatorPitch event on Thursday, November 7, at Miami’s Mana Tech, showcasing six of the University of Florida’s best startups to more than 150 attendees from South Florida’s dynamic investor and entrepreneurial community.

Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003

Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.

Soilcea Modified Sweet Orange Receives Favorable Decision

UF Startup Soilcea’s modified sweet orange, which reportedly has resistance to HLB, has been determined by the U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) to be neither a plant pest nor a plant that requires regulation under 7 CFR part 340.